Regadenoson .08 mg/mL

Regadenoson .08 mg/mL is an injectable solution used for specific medical imaging procedures. This pharmaceutical, manufactured by Hospira, Inc., is designed to enhance diagnostic accuracy in certain cardiovascular assessments.

Regadenoson .08 mg/mL is primarily used as a pharmacological stress agent in myocardial perfusion imaging (MPI). This process helps healthcare professionals evaluate blood flow to the heart muscle. The solution is administered intravenously to simulate the effects of physical exercise, aiding in the detection of coronary artery disease. Regadenoson .08 mg/mL is often utilized when patients are unable to undergo physical stress testing.

Common effects of Regadenoson .08 mg/mL may include flushing, headache, chest discomfort, and shortness of breath. These effects are typically mild and transient, resolving shortly after administration. Patients may also experience dizziness or nausea. It is important to monitor patients closely during and after the procedure to ensure their safety and comfort.

Regadenoson .08 mg/mL should be used with caution in patients with asthma, low blood pressure, or a history of seizures. It is essential to inform healthcare providers about any allergies or medical conditions before administration. The solution should be stored at room temperature and protected from light. Always follow the manufacturer's guidelines for handling and disposal.

Regadenoson .08 mg/mL may interact with certain medications, including those that affect heart rate or blood pressure. Patients should avoid caffeine and other stimulants before the procedure, as they can interfere with the accuracy of the imaging results. Always consult a healthcare provider for personalized advice regarding potential drug interactions.